Journals / Ege Tıp Dergisi / 2019 / Cilt: 58 - Sayı: 3

Photodynamic therapy in ophthalmology

Oftalmolojide fotodinamik tedavi

Pages
289–294
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the use of PDT in the treatment of AMD is limited because of the higher success of recently used vascular endothelial growth factor (VEGF) inhibitors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate the results of photodynamic therapy (PDT) using verteporfin in different types of choroidal neovascularization resulting from age-related macular degeneration (AMD).
📊
Key Findings & Data:Materials and Methods: Forty-two eyes of 40 patients were included in the study.
💡
Conclusion & Impact:However, the use of PDT in the treatment of AMD is limited because of the higher success of recently used vascular endothelial growth factor (VEGF) inhibitors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To evaluate the results of photodynamic therapy (PDT) using verteporfin in different types of choroidal neovascularization resulting from age-related macular degeneration (AMD). Materials and Methods: Forty-two eyes of 40 patients were included in the study. Visual acuity, contrast sensitivity and lesion characteristics in fluorescein angiography (FA) of the cases were recorded before and after PDT. The patients were evaluated at the 7th day, 6th week, 12th week, and afterwards, if no problem was observed, every 3 months in a year. We evaluated the success or failure rates of the treatment. Results: Mean age of the patients was 64.50±12.00 years. Eighteen of the lesions (43%) were pureclassical, 4 (9%) minimally-classical, 15 (36%) predominant-classical and 5 occult. Of these lesions, 31 (74%) were subfoveal and 11 (26%) juxtafoveal; 18 (43%) well-defined, and 28 (67%) poorly-defined. When examined in terms of lesion types, success rate was higher in predominant-classical group, but this difference was not statistically significant (p=0.062). Success was achieved in 30 of 31 eyes with subfoveal lesions (97%) and in 8 of 11 (73%) eyes with juxtafoveal lesions (p=0.049). The visual acuity level determined at the last visit in the successful group was significantly higher than that of the unsuccessful group (p=0.015). Statistically significant improvement in contrast sensitivity was achieved after treatment (p=0.028). Conclusion: PDT reliably reduces the risk of visual loss in subfoveal choroidal neovascularization due to AMD. However, the use of PDT in the treatment of AMD is limited because of the higher success of recently used vascular endothelial growth factor (VEGF) inhibitors.

Özet

Amaç: Yaşa Bağlı Makula Dejeneresansı (YBMD) sonucu gelişen koroid neovaskülarizasyonlarının farklı tiplerinde, verteporfin kullanılarak yapılan fotodinamik tedavinin (FDT) sonuçlarını değerlendirmektir. Gereç ve Yöntem: Ege Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim Dalı’nda YBMD'ye bağlı koroid neovaskülarizasyonlarında FDT uygulanmış 40 hastanın 42 gözü çalışma kapsamına alındı. Olguların tedavi öncesi ve sonrası görme keskinlikleri, kontrast duyarlılıkları ve floresein anjiografideki (FA) lezyon özellikleri kaydedildi. FDT uygulanmış hastaların 7. gün, 6. hafta, 12. hafta ve sonrasında ise bir sorun izlenmediği takdirde 1 yıl süre ile 3 ayda bir olan kontrolleri değerlendirildi. Hastaların 3 ay arayla çekilen FA görüntülerinde lezyonun sızdırma özelliklerine göre tedavinin başarısı değerlendirildi. Bulgular: Çalışmaya alınan 28 erkek, 12 kadın hastanın yaş ortalaması 64.50±12.00 yıldı. Lezyonların 18'i (%43) saf klasik, 4'ü (%9) minimal klasik, 15'i (%36) predominant klasik, 5'i ise okkült idi. Bu lezyonlardan 31'i (%74) subfoveal, 11'i (%26) ise juxtafoveal; 18'i (%43) iyi sınırlı, 28'i (%67) ise kötü sınırlıydı. Lezyon türleri açısından predominant klasik grupta başarı oranı daha yüksek bulundu, ancak bu fark anlamlı değildi (p=0.062). Subfoveal yerleşimli 31 gözden 30'unda başarı sağlanırken (%97), juxtafoveal yerleşimli 11 gözün 8'inde (%73) başarı sağlanmıştı (p=0.049). Tedavi öncesi lezyon çapı, görme keskinliği, kontrast duyarlılık ve uygulanan FDT sayısı açısından başarılı ve başarısız grup arasında anlamlı fark yoktu. Başarılı grupta son muayenede saptanan görme keskinliği düzeyi belirgin olarak yüksekti (p=0.015). Kontrast duyarlılıkta tedavi sonrasında istatistiksel olarak anlamlı düzelme saptandı (p=0.028). Sonuç: FDT, YBMD'ye bağlı gelişen özellikle subfoveal koroid neovaskülarizasyonlarında görme kaybı r sk n azaltmaktadır. Ancak son yıllarda yaygın kullanılan vasküler endotelyal büyüme faktörü inhibitörlerinin başarılı sonuçları nedeniyle FDT'nin YBMD tedavisinde sınırlı bir kullanımı mevcuttur.

🔖

Cite This Article

ATİK, S. Ş., AFRASHİ, F., AKKIN, C. (2019). Photodynamic therapy in ophthalmology. Ege Tıp Dergisi, Cilt: 58 - Sayı: 3, 289–294. https://ajindex.com/articles/165681

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Celli, JP, Spring, BQ, Rizvi, I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev 2010; 110(5): 2795-838
  2. Dougherty, TJ, Gomer, CJ, Henderson, BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90(12): 889-905. 3. van Straten, D, Mashayekhi, V, de Bruijn, HS, Oliveira, S, and Robinson, DJ. Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers (Basel) 2017; 9(2): 19
  3. Soubrane, G and Bressler, NM. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol 2001; 85(4): 483-95
  4. Bressler, NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119(2): 198-207
  5. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-- verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131(5): 541-60
  6. Boyer, DS, Schmidt-Erfurth, U, van Lookeren Campagne, M, Henry, EC, and Brittain, C. The Pathophysiology of Geographic Atrophy Secondary to Age-Related Macular Degeneration and the Complement Pathway as a Therapeutic Target. Retina 2017; 37(5): 819-835
  7. Ashraf, M, Souka, A, and Adelman, RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol 2018; 96(2): 120-133
  8. Van Leeuwen, R, Klaver, CC, Vingerling, JR, Hofman, A, and de Jong, PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 2003; 18(9): 845-54
  9. Bird, AC, Bressler, NM, Bressler, SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39(5): 367-74
  10. Yildirim, S, Akkin, C, Oztas, Z, Nalcaci, S, Afrashi, F, and Mentes, J. Direct Treatment Costs of Neovascular Agerelated Macular Degeneration and Comparison of Gained and/or Preserved Vision with Expenditure. Turk J Ophthalmol 2018; 48(1): 27-32
  11. Messmer, KJ and Abel, SR. Verteporfin for age-related macular degeneration. Ann Pharmacother 2001; 35(12): 1593-8
  12. Chakravarthy, U, Sou